Select language:  
1800 620 420
Close menu

Bridging the gap for young and middle-aged adults with blood cancer

The Leukaemia Foundation recently shared the successful trial and implementation of a dedicated peer support group for young-middle aged adults aged 20-49 living with blood cancer at the 16th Oncology Social Work Australia & New Zealand (OSWANZ) Conference. This innovative initiative addresses a critical gap in support services for this often-overlooked demographic.

  • Advocacy and policy
Read more

My voice matters

In 2017, Yani Zhao was on an incredible high after competing in the national powerlifting championships. The next day, she was diagnosed with blood cancer.

  • Acute myeloid leukaemia
  • Advocacy and policy
Read more

The Leukaemia Foundation welcomes Australian Government decision to ban using adverse genetic testing results in life insurance

The Leukaemia Foundation welcomes the Australian Government’s decision to ban the use of adverse genetic testing results in life insurance.

  • Advocacy and policy
Read more

World Marrow Donor Day 2024

Leukaemia Foundation staff come together to raise awareness for the Australian Bone Marrow Donor Registry (ABMDR), and the need for more Australians to register

  • Acute lymphoblastic leukaemia
  • Advocacy and policy
  • Treatments and side-effects
Read more

Treatment and transplant news

Once a blood cancer treatment is developed, it needs to be approved for sale in Australia and subsidised, or ‘listed’, otherwise the cost for the treatment can be unaffordable for many patients. The Medical Services Advisory Committee (MSAC) or Pharmaceutical Benefits Advisory Committee (PBAC) appraises a new treatment and provides advice to the Government on whether it should be publicly funded. This includes seeking consumer comments. Here’s a summary of recent new and recommended listings for blood cancer treatments. The Leukaemia Foundation provided advice and consumer comments to PBAC/MSAC in support of these therapies being available to patients.

  • Advocacy and policy
  • Treatments and side-effects
Read more

Addressing blood cancer challenges and improving patient outcomes

This issue of preventable deaths is now being addressed along with other priority actions around national standards of care and consistent access to clinical best practice.

  • Advocacy and policy
  • Research
  • Treatments and side-effects
Read more
Article #3 Tile

Referral to a haematologist takes 2+ months for 13% of blood cancer patients

A timely and accurate blood cancer diagnosis is critical to clinical best practice.

  • Advocacy and policy
  • Treatments and side-effects
Read more
Article #2 Tile

Access to best practice needed to reduce blood cancer mortality

Patients understand that clinical best practice care begins with an accurate and timely diagnosis.

  • Advocacy and policy
  • AML
  • Myeloma
  • Treatments and side-effects
Read more
Access to best practice needed to reduce blood cancer mortality

New Optimal Care Pathways to ensure consistent care for people living with blood cancer across Australia

  • Advocacy and policy
  • Media releases
Read more
Illustration of a tick in the middle of an Australian map, with National Standards of blood cancer care written around it

Support for submission to MSAC for genetic testing for blood cancers

  • Advocacy and policy
  • Research
Read more